---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004561"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:39:52.145993+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences reports Q2 net income, $40M SEC loss contingency, Phase 3 readout timeline

## Summary
- Q2 net income $6.2M vs net loss $26.4M in 2023, driven by non-cash warrant gain.
- Recorded $40M loss contingency for advanced discussions to resolve SEC investigation.
- Cash $207.3M at June 30, 2024; no debt; warrants fully exercised.
- Phase 3 RETHINK-ALZ top-line data expected by end of 2024; REFOCUS-ALZ mid-2025.
- Audit Committee vacancy due to director death; Nasdaq noncompliance; cure until Aug 2025.

## SEC filing metadata
- accession: 0001171843-24-004561
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184324004561/0001171843-24-004561-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184324004561/f8k_080824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004561
- JSON: https://secwatch.observer/filing/0001171843-24-004561.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004561.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.